Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 419-426

  Sponring, Andreas ^a,b   Filipiak, Wojciech ^a,b   Mikoviny, Tomas ^c   Ager, Clemens ^a,b   Schubert, Jochen ^b,e   Miekisch, Wolfram ^b,e   Amann, Anton ^a,b   Troppmair, Jakob ^a,d  

^a Universitatsklinik fur Chirurgie Innsbruck   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Gas chromatography mass spectrometry; Lung cancer; Thermodesorption; Volatile organic compounds (VOCs)

Indexed keywords

2 ETHYLHEXANOL; 2 METHYLBUTANAL; ACETALDEHYDE; BUTYL ACETATE; ISOBUTYRALDEHYDE; ISOHEXANE; ISOVALERALDEHYDE; TRYPSIN; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND;

ADSORPTION; ARTICLE; CANCER PATIENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPIRED AIR; FERMENTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

CELL LINE, TUMOR; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LUNG NEOPLASMS; VOLATILE ORGANIC COMPOUNDS;

EID: 61449223076     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Amann A and Smith D (eds.): Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring, Singapore, World Scientific 2005. See in particular Part B, p. 101 ff, Part C, p. 249 ff., and Part D, p. 373 ff.
2. Amann A, Spanel P and Smith D: Breath analysis: the approach towards clinical applications. Mini Rev Med Chem 7: 115-129, 2007.
3. Schubert J, Miekisch W and Nöldge-Schomburg G: VOC breath markers in critically ill patients: potentials and limitations. In: Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Amann A and Smith D (eds.). Singapore, World Scientific, pp. 267-292, 2005.
4. Risby T: Current status of clinical breath analysis. In: Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Amann A and Smith D (eds.). Singapore, World Scientific pp. 251-265, 2005.
5. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenberg J, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN and Schmitt P: Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark 3: 95-109, 2007.
6. Phillips M, Cataneo RN, Cummin AR, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA and Rom WN: Detection of lung cancer with volatile markers in the breath. Chest 123: 2115-2123, 2003.
7. Di Natale C, Macagnano A, Martinelli E, Paolesse R, D'Arcangelo G, Roscioni C, Finazzi-Agro A and D'Amico A: Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron 18: 1209-1218, 2003.
8. Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O, Balbi B, Bianchi L, Rusca M and Mutti A: Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res 6: 71, 2005.
9. Machado RF, Laskowski D, Deffenderfer O, Burch T, Zheng S, Mazzone PJ, Mekhail T, Jennings C, Stoller J K, Pyle J, Duncan J, Dweik RA and Erzurum SC: Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 171: 1286-1291, 2005.
10. Wehinger A, Schmid A, Mechtcheriakov S, Ledochowski M, Grabmer C, Gastl G and Amann A: Lung cancer detection by proton transfer reaction mass spectrometric analysis of human breath gas. Int J Mass Spec 265: 49-59, 2007.
11. Lebovitz HE: Diabetic ketoacidosis. Lancet 345: 767-772, 1995.
12. Chen S, Zieve L and Mahadevan V: Mercaptans and dimethyl sulfide in the breath of patients with cirrhosis of the liver. Effect of feeding methionine. J Lab Clin Med 75: 628-635, 1970.
13. Simenhoff ML, Burke JF, Saukkonen JJ, Ordinario AT and Doty R: Biochemical profile or uremic breath. N Engl J Med 297: 132-135, 1977.
14. Aghdassi E and Allard JP: Breath alkanes as a marker of oxidative stress in different clinical conditions. Free Radic Biol Med 28: 880-886, 2000.
15. Pabst F, Miekisch W, Fuchs P, Kischkel S and Schubert JK: Monitoring of oxidative and metabolic stress during cardiac surgery by means of breath biomarkers: an observational study. J Cardiothorac Surg 2: 37, 2007.
16. Smith D, Wang T, Sule-Suso J, Spanel P and El Haj A: Quantification of acetaldehyde released by lung cancer cells in vitro using selected ion-flow tube mass spectrometry. Rapid Commun Mass Spectrom 17: 845-850, 2003.
17. Chen X, Xu F, Wang Y, Pan Y, Lu D, Wang P, Ying K, Chen E and Zhang W: A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. Cancer 110: 835-844, 2007.
18. Byrne G, Lehmann L, Kirschbaum J, Borden E, Lee C and Brown R: Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res 6: 389-396, 1986.
19. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, Fuchs D and Amberger A: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T-cells. Clin Cancer Res 12: 1144-1151, 2006.
20. Brandacher G, Winkler C, Schroecksnadel K, Margreiter R and Fuchs D: Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr Drug Metab 7: 599-612, 2006.
21. Spanel P, Smith D, Holland TA, Al Singary W and Elder JB: Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion-flow tube mass spectrometry. Rapid Commun Mass Spectrom 13: 1354-1359, 1999.
22. Smith D and Spanel P: Selected ion-flow tube mass spectrometry, SIFT-MS, for on-line trace gas analysis of breath. In: Breath analysis for clinical diagnosis and therapeutic monitoring. Amann A and Smith D (eds.). Singapore, World Scientific Publishing Co. Pte. Ltd. pp., 2005.
23. Agostini M, Silva SD, Zecchin KG, Coletta RD, Jorge J, Loda M and Graner E: Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells. Oral Oncol 40: 728-735, 2004.
24. Kuhajda FP: Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202-208, 2000.
25. Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger DC and Grizzle WE: The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 31: 1068-1073, 2000.
26. Smith DWT, Sulé-Suso J, Spanel P and El Hadj A: Quantification of acetaldehyde released by lung cancer cell in vitro using selected ion-flow tube mass spectrometry, Rapid Commun Mass Spectrom 17: 845-850, 2003.
27. Homann N: Alcohol and upper gastrointestinal tract cancer: the role of local acetaldehyde production. Addict Biol 6: 309-323, 2001.
28. Balicki D: Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell 1: 485-487, 2007.
29. Chang JW, Jeon HB, Lee JH, Yoo JS, Chun JS, Kim JH and Yoo YJ: Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun 289: 507-512, 2001.
30. Patel M, Lu L, Zander DS, Sreerama L, Coco D and Moreb JS: ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer 59: 340-349, 2008.